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Introduction
Typically, osteoporosis randomized control trials have primary endpoints of vertebral fractures, since this is the most frequent fracture experienced in postmenopausal women. Hip fractures are seldom primary endpoints due to their infrequent nature in elderly patients, who are not often recruited to registration clinical trials. The main objective of the pivotal, phase 3 teriparatide studies in patients with postmenopausal osteoporosis was to investigate vertebral anti-fracture efficacy, while phase 4 trials were primarily aimed to investigate the effects on surrogate markers of bone strength and structure in a limited number of patients. Even though many of these studies included subjects at high risk for having osteoporotic fractures, the number of incident hip fractures was relatively small and insufficient to show statistically significant differences between groups. For example, the teriparatide clinical trial with the most hip fractures published to date reported only 9 such fractures [1] , while the pivotal, phase 3 trial of teriparatide in postmenopausal osteoporosis reported only 5 hip fragility fractures between the placebo and the teriparatide 20 µg treatment arms [2] . In the largest randomized clinical trial that included a teriparatide treatment arm, only 2 hip fractures were collected in the total clinical trial cohort [3] .
However, results from non-controlled, observational studies with larger patient cohorts, suggest that teriparatide may reduce the risk of hip fractures [4] [5] [6] [7] . Understanding the effects of treatment of teriparatide on hip fractures is important given the clinical impact and health economic importance of this type of fractures, and the lack of data from individual randomized clinical trials adequately powered to evaluate the efficacy of this drug on hip fractures.
The primary aim of this systematic review and meta-analysis was to evaluate the efficacy of teriparatide in the reduction of hip fractures in women and men with osteoporosis. The secondary objective was the investigation of the effects of teriparatide on upper limb fractures (i.e.
ACCEPTED MANUSCRIPT
A C C E P T E D M
A N U S C R I P T 6 humerus, forearm and wrist), in order to evaluate the fracture results in non-weight bearing bones.
Material and Methods
Literature search strategy
We designed this study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Guidelines [8] . The protocol was registered in the International Prospective
Register of Systematic Reviews, PROSPERO (registration number: CRD42018085635).
A comprehensive search strategy aimed to identify RCTs that reported non-spine fractures either as an efficacy or safety endpoint, published in English, French or Spanish until 22 November 2017. Literature searches on MEDLINE (OVID interface, 1948 onwards) and EMBASE (OVID interface, 1974 onwards) were performed. Keywords were identified with medical subject headings (MeSH) and text words related to "teriparatide" and "parathyroid hormone (1-34)".
Additional sources included searches in clinical trial repositories (clinicaltrials.gov and EUDRAC), and contact with main authors and manufactures that owned study reports of clinical trials on teriparatide that missed some fracture site details in the peer-reviewed publications.
Selection criteria
The main outcome of interest was the incidence of fragility, low trauma hip fractures following teriparatide treatment. Eligible studies met the following inclusion criteria: (1) RCTs with study participants treated according to the approved indications for the use of teriparatide in the USA, Europe and Japan (i.e.; postmenopausal and male osteoporosis, glucocorticoid-induced osteoporosis); (2) minimum of 6-month treatment exposure; (3) a maximum treatment duration
as approved (i.e.; 24 months), at the approved dose (20 µg/day subcutaneously) [9] , and (4) controlled with placebo or other active anti-osteoporosis drug, either commercially available, or under clinical development. Narrative reviews, observational studies, comments, opinion pieces, methodological reports, editorials, and letters were excluded. Reviews were screened to check for potential additional studies that were not published as standalone papers.
Following the screening of titles and abstracts, duplicates were removed. If multiple reports were available from the same study, fracture data from the most recent report were included. Two authors (ADP and FM) independently analyzed the titles and abstracts and then performed the study selection and evaluation of quality and data extraction of the full papers. Discrepancies were resolved by consensus between the reviewer authors.
Data extraction and management
Data extracted from each study included participants, interventions, description of the comparators, and outcomes with the following specific items: first author, reference, year of publication, control group, participants' characteristics [gender, age], study design, clinical development phase, incident selected non-vertebral fractures, type of fracture endpoint (efficacy or safety), and duration of treatment. In the case of forearm and wrist fractures, the fracture site term was kept as reported in the original publication; fractures reported at the "radius" were included in the forearm fractures analysis, while fractures reported at "carpal bones" were included in the wrist fractures analysis. The lack of detailed results of other individual nonvertebral fracture sites in most of the publications precluded a pooled analysis of all nonvertebral fractures.
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For consistency with the primary objective, we focused the analysis on low trauma, fragility upper limb fractures when that information was explicitly disclosed in the publications.
Quality assessment
The scale recommended by the Cochrane Collaboration [10] was used to assess the methodological quality of identified studies as well as the risk of bias of the individual included.
The major criteria of the checklist were randomization, double blind (both patients and researcher/assessor), comparability of treatment groups, available follow-up information and equal treatment used for treatment groups. Each criterion might be answered in three ways: yes (adequate information), no (inadequate information), or unclear information.
Data synthesis and statistical analysis
As it was expected that many studies would report zero fractures in at least one of the treatment arms, two procedures were applied to estimate the risk of fracture: odds ratio (OR) by the Peto`s method and Mantel-Haenszel with empirical correction, with 95% confidence intervals (CI) [11] .
Differences were considered statistically significant when p-value was <0.05. If there were more than two comparators in the same trial, the results of the comparators were pooled initially, and separated in sensitivity analysis (placebo and active comparators). A random effects model was not considered a priori, as heterogeneity is very uncommon when the data are sparse. Statistical heterogeneity was tested using the Q test (significance level: 0.1) and I 2 statistic (0% to 40%:
might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity). Meta-regression procedures were applied to ascertain whether mean age and duration of trial had an influence on
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A pre-planned sensitivity analysis was performed by removing the two clinical trials that did not report the hip fracture details in the peer-reviewed publications, but in clinical study reports filed by the studies sponsor [14, 15] .
Analyses were performed using the Stata 15 statistical package (College Station, TX, USA).
Subgroup analysis
To address heterogeneity among study populations, pre-specified subgroup analyses were performed as follows: type of comparator (placebo or active-treatment osteoporosis drug), type of randomization (double-blind or open-label), patient characteristics (age and gender) and follow-up period duration.
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Results
Summary of searches and study selection process
A total of 609 citations were identified through searches plus 4 on-file clinical trial reports, of which 404 records remained after removal of duplicates. After screening via titles and abstracts, 372 articles and study reports remained for further evaluation. Following further evaluation, 310 more articles were excluded for the following reasons: not a RCT, off-label use of teriparatide, non-approved doses, testing of combination therapies with other anti-osteoporosis drugs, or they were non-human studies. In many instances, more than one exclusion criteria applied. Sixty-two records remained for full-text assessment, 39 of them were further excluded because the index drug was weekly teriparatide, no fracture results were included, or they were published in languages other than English, French or Spanish. Therefore, a total of 23 clinical trials published between 2001 and 2017 were included in the current meta-analysis ( Figure 1 ).
Detailed information of the included studies is summarized in Table 1 . Twenty-three RCTs were included, representing data on 8644 subjects, 3893 of them treated with teriparatide. Eight trials were double-blind during the full study follow-up [2, 14, [16] [17] [18] [19] [20] [21] , 12 open-label [3, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , and 3 trials had a mixed design with an initial double-blind phase (6 to 12 months duration) followed by an open-label phase for up to 18 to 24 months [1, 15, 34] (Table 1 ). There were 4 placebocontrolled trials [2, 15, 16, 18] , 17 active-controlled trials [1, 14, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , one three-arm study [3] , and one multiple-arm study [31] [29, 30, 32] , abaloparatide [3] and romosozumab [31, 33] . In the control group, 1667 (35.1%) patients received placebo and 3084
(64.9%) patients an active comparator (Table 2) . Seventeen studies were of women with postmenopausal osteoporosis, 3 studies included exclusively men [16, 20, 28] , and 3 studies included a mixed population of men and women [1, 14, 15] (Table 1) . Of all subjects, there were 545 men (6.3% of the total subjects) ( Table 1 ). Two studies were of patients with glucocorticoidinduced osteoporosis (14,28) for a total of 520 patients (6.0% of the total included subjects).
Overall, subjects' mean age (SD) was 67.0 (4.5) years, and the median teriparatide treatment duration was 18 months (range: 6 to 24 months).
Risk of bias assessment
All included studies had a low risk of bias according to randomization, allocation concealment, and comparability of intervention groups at the beginning of the trial and equal treatment of intervention groups (Supplemental Table 1 ). No evidence of publication bias was detected using funnel plot or Egger's test (intercept = 0.94; 95% CI: -3.00 to 1.12, p=0.315).
2.3.Pooled estimate of the effect of teriparatide on hip and upper limb bones fractures
A total of 34 incident hip, 31 humerus, 31 forearm, and 62 wrist fractures were reported (Table   2 ). In 14 studies, representing 1651 patients, no hip fractures were reported [16-18,20, There was no indication for a relationship between fracture risk reduction and patients' age or the clinical trial duration. Analysis by gender was not feasible given the low number of hip fractures in male subjects (n=1).
After removing the 2 hip fractures that were not described in the in the peer-reviewed papers 
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14 treatment duration increased [4] . Finally, the real-world experience of teriparatide in reducing the risk of fractures showed hip fractures decreased as adherence and persistence to teriparatide treatment increased [6] .
Of note, the hip fracture efficacy with teriparatide was detected after a relatively short median treatment duration of 18 months, with a maximum treatment duration in the included studies of 24 months. The pivotal trial for teriparatide [2] was discontinued early because of safety concerns raised by preclinical findings of increased risk of osteosarcoma in rats 
Highlights:
 Hip fractures are the most devastating complications of osteoporosis.
 Evidence of hip fracture reduction with teriparatide is limited.
 We conducted a meta-analysis of randomized clinical trials of teriparatide.
 Teriparatide showed a 56% reduction of hip fractures versus controls.
 Significant effects on fractures of upper limb bones were not observed.
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